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Abstract
Background:  The genes encoding proteins in the thrombomodulin-protein C pathway are
promising candidate genes for stroke susceptibility because of their importance in thrombosis
regulation and inflammatory response. Several published studies have shown that the Ala455Val
thrombomodulin polymorphism is associated with ischemic heart disease, but none has examined
the association with stroke. Using data from the Stroke Prevention in Young Women Study, we
sought to determine the association between the Ala455Val thrombomodulin polymorphism and
the occurrence of ischemic stroke in young women.
Methods: All 59 hospitals in the greater Baltimore-Washington area participated in a population-
based case-control study of stroke in young women. We compared 141 cases of first ischemic
stroke (44% black) among women 15 to 44 years of age with 210 control subjects (35% black) who
were identified by random digit dialing and frequency matched to the cases by age and geographical
region of residence. Data on historical risk factors were collected by standardized interview.
Genotyping of the thrombomodulin Ala455Val polymorphism was performed by pyrosequencing.
Results: The A allele (frequency = 0.85) was associated with stroke under the recessive model.
After adjustment for age, race, cigarette smoking, hypertension, and diabetes, the AA genotype,
compared with the AV and VV genotypes combined, was significantly associated with stroke (odds
ratio 1.9, 95% CI 1.1–3.3). The AA genotype was more common among black than white control
subjects (81% versus 68%) but there was no significant interaction between the risk genotype and
race (adjusted odds ratio 2.7 for blacks and 1.6 for whites). A secondary analysis removing all
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probable (n = 16) and possible (n = 15) cardioembolic strokes demonstrated an increased
association (odds ratio 2.2, 95% CI 1.2–4.2).
Conclusions: Among women aged 15 to 44 years, the AA genotype is more prevalent among
blacks than whites and is associated with increased risk of early onset ischemic stroke. Removing
strokes potentially related to cardioembolic phenomena increased this association. Further studies
are needed to determine whether this polymorphism is functionally related to thrombomodulin
expression or whether the association is due to population stratification or linkage to a nearby
functional polymorphism.
Background
Thrombosis is a dynamic balance between factors that
promote clot formation, antithrombotic mechanisms,
and fibrinolysis. Central to this balance is the thrombo-
modulin-protein C antithrombotic mechanism. Throm-
bomodulin forms a 1:1 complex with thrombin on the
vascular endothelium, thereby inhibiting the procoagu-
lant actions of thrombin and converting protein C to acti-
vated protein C [1]. Activated protein C promotes
fibrinolysis, inhibits thrombosis by inactivating clotting
factors Va and VIIIa, and reduces inflammation by
decreasing white blood cell and nuclear factor kappa-B
activation [2-5]. These relationships are demonstrated in
Figure 1. Because of the central role that the thrombo-
modulin-protein C pathway plays in thrombosis regula-
tion and inflammatory response, the genes encoding
these pathway proteins are promising candidate genes
regarding stroke susceptibility.
The thrombomodulin gene (THBD) maps to chromo-
some 20p11.2, contains a single exon and no introns, and
spans 4 kb (OMIM 188040, UniGene NM_000361, Locus
Link 7056). The thrombomodulin protein is expressed
primarily on the luminal surface of vascular endothelial
cells and consists of 557 amino acids (aa) (60,300 Dal-
ton): an N-terminal lectin-like module (aa 1–154), a
hydrophobic region (aa 155–222), six epidermal growth
factor (EGF)-like modules (aa 223–462), a serine and
threonine rich region (aa 463–497), a single transmem-
brane segment (aa 498–521), and a short cytoplasmic tail
(aa 522–557) [6]. A single nucleotide polymorphism
(C→T) at position +1418 (C1418T) encodes for an aa
change from alanine to valine at protein position 455
(Ala455Val) [7]. The location of this aa variation corre-
sponds to the sixth EGF region of the thrombomodulin
protein as seen in Figure 2. This location has been shown
to be responsible for the high-affinity binding of
thrombin and for the suspension of thrombin at a specific
position above the endothelial surface in relation to other
cofactors, thereby producing optimal protein C activation
by thrombin [2,8].
A few studies have shown that the THBD Ala455Val poly-
morphism is associated with ischemic heart disease
Thrombomodulin / Protein-C relationships and function Figure 1
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[9,10], but we know of no prior reports examining this
polymorphism's association with stroke. Using data from
the Stroke Prevention in Young Women Study [11], we
sought to determine the association between the THBD
Ala455Val polymorphism and the occurrence of ischemic
stroke in young women. In addition, because cardioem-
bolic stroke has a lesser degree of familial aggregation
[12], we performed a secondary analysis excluding cases
with cardioembolic etiologies.
Methods
The Stroke Prevention in Young Women Study (SPYW) is
a population-based case-control study that was initiated
to examine risk factors for ischemic stroke in young
women. In that study the term "population-based" means
that cases and their comparison group were identified
from the same defined population. The study area
included all of Maryland (except the far Western panhan-
dle), Washington DC, and the southern portions of both
Pennsylvania and Delaware. Cases were female patients
15 to 44 years of age with a first cerebral infarction as
identified by discharge surveillance at 59 regional
hospitals and through direct referral by regional neurolo-
gists. The methods for discharge surveillance, chart
abstraction, and case adjudication have been described
previously [11,13,14]. The adjudication of stroke cases
was performed blinded to genetic information. Stroke
cases were classified as having a probable, possible or
undetermined etiology as per prior description [13,14].
Control subjects were women without a history of stroke.
They were identified by random digit dialing and were fre-
quency matched to the cases by age and geographic region
of residence. The original SPYW study consisted of 227
cases and 342 controls. DNA samples were available for a
subset of this population consisting of 141 cases and 210
controls.
We performed THBD genotyping at the Ala455Val poly-
morphism for 141 cases and 210 control subjects. This
included all case and control samples that were available
at that time. Genotyping was performed blinded to case-
control status. Genomic DNA was extracted from stored
peripheral blood lymphocytes by using standard proto-
cols (Gentra Systems, Minneapolis, MN). The THBD
Ala455Val polymorphism was determined by pyrose-
quencing. The single-nucleotide polymorphism region of
the gene was amplified by polymerase chain reaction
(PCR) with the use of published primers [10] except that
we labeled the reverse primer with biotin. PCR was per-
formed in 40 µl reactions containing 40 ng of genomic
DNA, 15 pmol each of forward and reverse primer, 1.5 U
of Amplitaq (Applied Biosystems, Foster City, CA) and
MasterAmp PCR PreMix D (Epicenter, Madison, WI). The
resulting biotinylated PCR product was bound to strepta-
vidin-coated Sepharose HP beads (Amersham Pharmacia
Biotech, Uppsala, Sweden) and the product was
denatured according to the manufacturer's protocol (PSQ
96 Sample Preparation Kit, Pyrosequencing AB, Uppsala,
Sweden). Following denaturation, an internal sequencing
primer (5'-CGACTCGGC CCT T-3') was annealed to the
bound single-stranded DNA. We used an automated pyro-
sequencing instrument (PSQ96, Pyrosequencing AB,
Uppsala, Sweden) to perform the genotyping [15,16]. The
reactions were performed at 28°C and contained the
bound single-stranded DNA with annealed sequencing
primer, enzymes (DNA polymerase, apyrase, luciferase,
and activating transcription factor sulfurylase), nucle-
otides (dTTP, dGTP, dCTP, or dATPαS), and substrate
(luciferin) supplied by the manufacturer. We monitored
continuously the output from the charge-coupled device
as a pyrogram, and we analyzed manually the results from
the completed sequencing reactions by visually inspecting
each program. The validity of the method was confirmed
by fluorescent dye terminator sequencing of a subset of
samples using standard protocols on an ABI 3100 genetic
analyzer (Applied Biosystems, Foster City, CA).
We assessed the following potential confounders of the
association between the alleles of the THBD Ala455Val
polymorphism and stroke: age, race, current cigarette
smoking, hypertension, diabetes mellitus, history of
angina or myocardial infarction (angina/MI), use of oral
contraceptive pills (OCP) or hormone replacement ther-
apy (HRT), sickle cell disease, and sickle cell trait. Age,
race, current cigarette smoking status, use of OCP or HRT
was determined by subject reports (or proxy report, if a
participant was unable to answer). Hypertension and dia-
betes mellitus, sickle cell disease or sickle cell trait were
determined by asking study participants (or a proxy) if a
physician had ever told them that they had the condition.
We compared means by t tests and proportions by χ2
tests. The probability values presented are based on two-
sided tests. Because of the low frequency of the V455
allele, we compared the frequency of the combined AV/VV
genotype between cases and controls. Adjusted odds
ratios derived from logistic regression were used to deter-
mine whether the presence of the Ala455Val test allele was
associated with an increased risk for stroke after differ-
ences in age, race, current cigarette smoking, hyperten-
sion, and diabetes mellitus were controlled for.
Additional analyses included: 1). adding ischemic heart
disease (angina/MI) into the logistic regression model; 2).
evaluation for interactions between genotype and OCP/
HRT 3). an analysis excluding sickle cell trait, and 4). an
analysis excluding cardioembolic strokes.BMC Neurology 2004, 4:21 http://www.biomedcentral.com/1471-2377/4/21
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Results
Subject characteristics
Characteristics by case-control status are described in
Table 1. The mean age of the cases (i.e., women with a first
cerebral infarction) was 35.5 years and the mean age of
control subjects was 36.1 years. Cases were more likely
than control subjects to be black (44.0% versus 34.8%, p
= 0.12), and were significantly more likely to currently
smoke cigarettes (p < 0.001), to have hypertension (p <
0.01), diabetes (p < 0.001) and history of angina/MI (p <
0.001). No study subjects reported sickle cell disease,
however 6 cases and 5 controls reported sickle cell trait
(non-significant difference). Twenty cases and 34 controls
reported use of oral contraceptive pills (OCP) or hormone
replacement therapy (non-significant difference).
Genotype and vascular risk factor distributions
The distribution of genotypes was in Hardy Weinberg
equilibrium for the pooled set of cases and controls, both
in total and by race.
Among control subjects, the prevalence of the AA geno-
type was 81% (59/73) for blacks and 68% (93/137) for
whites. The relationship between the Ala455Val geno-
types and selected stroke risk factors in control subjects is
summarized in Table 2. Blacks were significantly more
likely to have the AA genotype than the AV and VV geno-
types combined (38.8% vs. 24.1%, p < 0.05). In contrast,
there were no significant differences in prevalence of
hypertension, diabetes, angina/MI, or sickle cell trait
between carriers and non-carriers of the V allele, nor did
the frequency of cigarette smoking or OCP/HRT use differ
significantly between the two groups.
Genotype risk
Table 3 shows the association of the AA genotype with
stroke, stratified by race and other vascular risk factors.
The association between the AA genotype and stroke was
2.7 (95% CI 0.9–8.0) among blacks and 1.6 (95% CI 0.8–
3.2) among whites. Since logistic regression analysis did
not show a significant interaction by race (i.e., the effect of
the AA genotype did not differ significantly between
blacks and whites), subsequent analyses were conducted
on the combined sample. After adjustment for age, race,
cigarette smoking, hypertension, and diabetes, the AA
genotype was found to be significantly associated with
stroke compared with the AV and VV genotypes (OR 1.9,
95% CI 1.1–3.3).
The strength of association between the AA genotype and
stroke remained unchanged including history of angina or
myocardial infarction in the logistic regression model
(OR 1.9, 95% CI 1.1–3.3). Neither OCP/HRT use, nor
sickle cell trait demonstrated an interaction with genotype
and additional adjustment for these factors did not alter
the association between the AA genotype and stroke.
Stroke subtype
Among the 141 stroke patients, 70 (50%) had a least 1
probable cause, 30 (21%) had no probable cause but a
least one possible cause, and 41 (29%) were indetermi-
nate. Table 4 shows the distribution of probable and pos-
sible causes. "Other determined causes" of stroke
included hematologic disorders, nonatherosclerotic
vasculopathy (eg, vasculitis and dissection), migraine,
drug abuse and stroke associated with oral contraceptive
or exogenous estrogen use.
A secondary analysis removing all probable (n = 16) or
possible (n = 15) cardioembolic strokes was performed
using the same adjusted model including age, race, smok-
ing, hypertension, and diabetes. An increased association
between non-cardioembolic stroke and the AA genotype
was demonstrated (odds ratio 2.2, 95% CI 1.2–4.2).
Discussion
In our study of the THBD Ala455Val polymorphism, the
prevalence of the AA genotype among our control popu-
lation was similar to that previously reported for the
Atherosclerosis Risk in Communities (ARIC) Study popu-
lation [10]. Our results indicate a positive association
between the AA genotype and stroke among women aged
15 to 44 years. Furthermore, an increased association was
Table 1: Characteristics, by case-control status
Case (N = 141) Control (N = 210) p-value
Mean age (years) 35.5 36.1 .31
Black (%) 44.0 34.8 .12
Current Smokers (%) 45.4 26.7 <.001
Hypertension (%) 27.7 13.3 <.01
Diabetes mellitus (%) 13.5 3.3 <.001
Angina/MI (%) 14.9 4.3 <.001
Table 2: Characteristics among control subjects, by 
thrombomodulin genotype status
AA (n= 152) AV/VV (n= 58) p-value
Mean age (years) 36.5 34.9 0.17
Black (%) 38.8 24.1 <.05
Current Smokers (%) 26.3 27.6 0.86
Hypertension (%) 11.2 19.0 0.18
Diabetes Mellitus (%) 4.0 1.7 0.34
Angina/MI (%) 2.4 1.9 0.26BMC Neurology 2004, 4:21 http://www.biomedcentral.com/1471-2377/4/21
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demonstrated with the removal of all probable or possible
cardioembolic strokes, a finding consistent with a recent
meta-analysis demonstrating that cardioembolic stroke
appears to have a smaller familial (or genetic) component
that other subtypes of ischemic stroke [12]. Vascular risk
factors were not significantly associated with specific gen-
otypes in either analysis.
Several recent studies evaluating the THBD  Ala455Val
polymorphism and coronary artery disease (CAD) have
yielded conflicting results. A Swedish case-control study
found the alanine allele was associated with CAD [9]. In
contrast, the American prospective ARIC study found the
valine allele (AV plus VV) was associated with an increase
in CAD risk in both blacks (OR 4.4, 95% CI 1.5–12.9) and
whites (OR 1.4, 95% CI 0.9–2.1), although the
association attained statistical significance only in blacks
[10]. A British case-control study found no association at
all between the THBD  Ala455Val polymorphism and
CAD [17]. Consistent with the Swedish results [9], we
observed an association between the alanine allele at this
locus and stroke onset at a young age. It is unclear whether
the conflicting information regarding the THBD
Ala455Val polymorphism, ours included, is due to popu-
lation-stratification bias, a functionally neutral polymor-
phism that serves as a marker for a nearby functional
Table 3: Frequency of the THBD Ala455Val AA genotype in cases and controls (proportion with AA genotype in parentheses) as 
stratified by race and other stroke risk factors; with associated crude and adjusted odds ratios
Risk Factor Percentage of cases with 
the AA genotype 
(proportion)
Percentage of Controls 
with the AA genotype 
(proportion)
Crude OR ^ (95% CI) Adjusted OR*^ (95% CI)
White 79% (62/79) 68% (93/137) 1.7 (0.9–3.3) 1.6 (0.8–3.2)
Black 87% (54/62) 81% (59/73) 1.8 (0.4–7.9) 2.7 (0.9–8.0)
Current smoking 84% (54/64) 71% (40/56) 2.2 (0.9–5.3) 3.0 (1.1–7.8)
No current smoking 81% (62/77) 73% (112/154) 1.6 (0.8–3.0) 1.5 (0.7–2.9)
Hypertension 85% (33/39) 61% (17/28) 3.6 (1.1–11.3) 5.7 (1.4–22.6)
No hypertension 81% (83/102) 74% (135/182) 1.5 (0.8–2.8) 1.6 (0.8–3.0)
Diabetes** 84% (16/19) 86% (6/7) Not performed Not performed
No Diabetes 82% (100/122) 72% (146/203) 1.8 (1.0–3.1) 1.9 (1.1–3.4)
Angina/MI ** 86% (18/21) 56% (5/9) Not performed Not performed
No Angina/MI 82% (98/120) 73% (147/201) 1.6 (0.9–2.9) 1.7 (.95–3.1)
Overall 82% (116/141) 72% (152/210) 1.8 (1.1–3.0) 1.9 (1.1–3.3)
* Each variable adjusted for age, race, smoking, hypertension, and diabetes (less the stratified variable). Overall model and Angina/MI adjusted for 
age, race, smoking, hypertension, and diabetes. Including Angina/MI in adjusted overall model demonstrated no change in association (OR = 1.9 95% 
CI = 1.1–3.3).
** Insufficient sample size to perform diabetic or angina/MI analyses.
^ The combined AV and VV genotypes within each strata serve as the reference group in all analyses, with the crude OR and adjusted OR assigned 
a reference value of 1.0.
Table 4: Etiologies among cases with a probable or possible cause of stroke
Probable Causes1 (n = 70) Possible Causes2 (n = 30)
Large-artery autherosclerosis 9 8
Cardioembolism* 16 14
Lacune 7 3
Other determined cause** 38 5
1 One patient had 2 probable causes, but only 1 cause is listed according to the following hierarchy: large-artery atherosclerosis > cardioembolism 
> lacune> other determined cause.
2 Most patients had multiple possible causes, but only 1 cause is listed per patient according to the same hierarchy as for probable causes.
* Note one probable case attributed to "other determined cause", also had possible cardioembolism as an etiology, this case was removed from the 
secondary analysis. A total of 31 cases were removed from the secondary analysis on the basis of either probable (n = 16) or possible (n = 15) 
cardioembolism as the stroke etiology.
** Other determined causes included: Probable = 38, (10 non-atherosclerotic vasculopathy, 13 hematologic, 4 migraine, 6 oral contraceptive or 
exogenous estrogen use, 5 other drug related). Possible = 5, (3 hematologic, 2 migraine).BMC Neurology 2004, 4:21 http://www.biomedcentral.com/1471-2377/4/21
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mutation (linkage disequilibrium), or the true existence
of different associations in the different study
populations.
Population-stratification bias is due to confounding by
population admixture [18]. An unidentified subpopula-
tion can confound the association between a genotype
and disease if the subpopulation is associated with the
genotype under study and the risk of disease. Because our
results indicate that blacks have a higher prevalence of the
AA genotype and have an increased risk of early-onset
stroke, the AA genotype might be a marker for African
ancestry in general rather than a marker for increased
stroke susceptibility.
The THBD Ala455Val locus may be in linkage disequilib-
rium with an unobserved "high-risk" susceptibility locus.
Linkage disequilibrium is a function of the history of the
population, and thus true associations can occur in one
population and not another.
Our results are also consistent with a causal association
between stroke and the THBD Ala455Val polymorphism,
thereby defining a susceptibility locus for the disease. An
important criterion for a true susceptibility locus is that
the polymorphism is associated with a change in protein
expression or function. The THBD Ala455Val polymor-
phism has not been associated with variation in soluble
thrombomodulin concentrations [19], but soluble
thrombomodulin levels do not necessarily indicate the
functional status of thrombomodulin on the endothelial
surface. The Ala455Val polymorphism resides within a
critical region for thrombomodulin function, specifically
within the sixth EGF region. Epidermal growth factor
(EGF) regions 4, 5, and 6 within the thrombomodulin
molecule (see Figure 1) appear to play critical roles in the
activation of protein C by thrombin [2,8,20,21]. Further-
more, this contiguous EGF segment is the minimal func-
tional fragment of the thrombomodulin cofactor that can
switch the specificity of thrombin from a procoagulant to
an anticoagulant enzyme [21,22]. Furthermore, two poly-
morphisms close to the Ala455Val polymorphism,
Arg385Ser and Pro477Ser, have been shown to influence
the expression and function of thrombomodulin in a tis-
sue culture model [23].
Conclusions
Thrombomodulin has not previously been examined as a
candidate gene for stroke susceptibility. We found that
among women aged 15 to 44 years, the AA genotype is
more prevalent among blacks than whites and is associ-
ated with increased risk of early-onset ischemic stroke.
Removing strokes potentially related to cardioembolic
phenomena increased this association. Further studies are
needed to determine whether this association is due to
population stratification, linkage to a nearby functional
polymorphism, or variation in thrombomodulin expres-
sion or function.
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